BioMarin Pharmaceutical Inc. announced that Robert Baffi, Ph.D., Executive Vice President, Technical Operations, will participate in a gene therapy manufacturing focused fireside chat at the RBC Capital Markets Global Healthcare Conference on May 21 at 8:00am ET in New York City.
SAN RAFAEL, Calif., May 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Robert Baffi, Ph.D., Executive Vice President, Technical Operations, will participate in a gene therapy manufacturing focused fireside chat at the RBC Capital Markets Global Healthcare Conference on May 21 at 8:00am ET in New York City. To access the live webcast, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following each event.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The Company’s portfolio consists of several commercial products and multiple clinical and pre-clinical product candidates for the treatment of various diseases. For additional information, please visit www.biomarin.com.
| Contacts: | |
| Investors | Media |
| Traci McCarty | Debra Charlesworth |
| BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
| (415) 455-7558 | (415) 455-7451 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-participate-in-2019-rbc-capital-markets-global-healthcare-conference-on-may-21-in-new-york-city-300851391.html
SOURCE BioMarin Pharmaceutical Inc.
Company Codes: NASDAQ-NMS:BMRN
